Thymosin Alpha-1 vs Thymosin Beta-4: Two Unrelated Peptides With One Family Name

Why two unrelated peptides share one name

“Thymosin” began as the name of an activity rather than a molecule. Goldstein and White first extracted thymosin from calf thymus as a lymphocyte growth factor in the 1960s, and their working preparation, thymosin fraction 5, turned out to contain many peptides. Goldstein’s group proposed a nomenclature for the fraction 5 peptides in 1977, in the paper that reported the sequence of thymosin alpha-1. As later reviews describe it, the system groups the peptides by isoelectric point (pI): an α group below pI 5, a β group between 5 and 7, and a γ group above 7.

So the thymosin alpha vs beta labels record how acidic each peptide was in that extract — a matter of charge, not ancestry. The sequences bear this out. Counting from the UniProt records, thymosin alpha-1 carries nine acidic residues (aspartate and glutamate) against four basic lysines; thymosin beta-4 carries eleven against nine. In both, acetylation of the N-terminal amine removes a positive charge. These two were the first fraction 5 peptides to be fully characterized, according to a 2016 review.

The family name misleads about location, too. Hannappel and colleagues found thymosin beta-4 in many rat and mouse tissues, at high levels in peritoneal macrophages and in athymic mice, and concluded that it does not come only from the thymus. Prothymosin alpha, the precursor of thymosin alpha-1, has been detected in all tissues, according to the 2016 review, and a 2012 review calls it “a ubiquitous polypeptide”. As with many research compounds, how peptide names arise says more about the history of a discovery than about the molecule, and the family of thymus peptides holds several other members with equally historical names.

Thymosin alpha-1: the front end of a larger protein

Goldstein’s group isolated thymosin alpha-1 from fraction 5 and sequenced it in 1977, describing “a heat stable, highly acidic molecule composed of 28 amino acid residues”. It is not encoded on its own. UniProt records it as residues 2–29 of prothymosin alpha, a nuclear protein of 111 residues as encoded by the PTMA gene on chromosome 2; in the processed form the initiator methionine is removed and serine 2 is acetylated. Thymosin alpha-1 is therefore the first 28 residues of the 110-residue N-terminally processed chain, about a quarter of it.

Whether free thymosin alpha-1 exists in tissues in meaningful amounts has been debated. In 1984 Haritos, Goodall and Horecker identified prothymosin alpha as the major form in rat thymus that reacts with thymosin alpha-1 antiserum, and proposed that it is probably the native polypeptide from which thymosin alpha-1 is generated during isolation. A 2016 review recounts that when Hannappel’s group extracted calf thymus in a way that limited proteolysis, thymosin beta-4 was the major component and thymosin alpha-1 was absent or present only in trace amounts. On the other hand, a 2003 study reported that legumain, a lysosomal asparaginyl endopeptidase, cuts prothymosin alpha to thymosin alpha-1 in vitro, and its authors concluded that thymosin alpha-1 occurs naturally in diverse mammalian tissues rather than as an extraction artefact.

Synthetic thymosin alpha-1, under the generic name thymalfasin, “is now approved in over 35 countries”, according to a 2023 review in Molecules. Our thymosin alpha-1 research guide covers its clinical record in detail; here only the contrast matters.

Thymosin beta-4: an actin-sequestering peptide

Low, Hu and Goldstein sequenced bovine thymosin beta-4, also from calf thymus, in 1981: 43 residues with an acetylated N-terminus, which they described as “a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations”. Its later identity lies elsewhere. In human cells it is the product of the TMSB4X gene on the X chromosome, which encodes 44 residues; the initiator methionine is removed and serine 2 is acetylated, leaving a mature chain of 43 (UniProt P62328). Unlike thymosin alpha-1, it is a whole protein, not a piece of one. A figure of 44 residues corresponds to the encoded sequence, initiator methionine included.

Thymosin beta-4’s main known role in cells is binding actin. UniProt describes it binding actin monomers (G-actin) and inhibiting their polymerization, and Sanders, Goldstein and Wang showed in 1992 that it is a potent regulator of actin assembly in living cells. That is why it is called an actin-sequestering peptide: by holding monomers, it controls how much actin is free to build filaments. It is also the dominant member of its family, “accounting for 70%–80% of β-thymosin”, according to a 2021 review. UniProt annotates its first four residues, Ac-SDKP, as a separate hemoregulatory peptide with a literature of its own — an early reminder that findings for fragments and for the whole protein must be kept apart.

Thymosin alpha-1 vs thymosin beta-4, side by side

Laid out property by property, the two share almost nothing beyond a source and an opening pair of residues.

The shared start, an acetylated serine followed by aspartate in both chains, is the kind of coincidence two short sequences can produce: two residues out of 28 and 43, and the match ends there. UniProt’s family assignments, not the name, are the reliable guide to relatedness.

What each body of research shows, and what it doesn’t

The two literatures differ in kind as well as size. For thymosin alpha-1, mechanistic studies reviewed by Tao and colleagues in 2023 describe it inducing the maturation of dendritic cells through Toll-like receptors. Its literature also includes clinical trials, among them a multicentre phase 3 trial published in The BMJ in 2025, which enrolled 1,106 adults with sepsis at 22 centres in China and “found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality”.

The thymosin beta-4 literature centres on actin, cell migration and angiogenesis, and on animal models of injury to the heart, cornea, kidney, liver and skin, as reviewed by Xing and colleagues in 2021; most of the work they review is preclinical. Clinical trials have tested specific formulations, such as eye drops. In a 2015 phase 2 trial that randomized 72 participants with dry eye, for example, neither primary endpoint differed significantly from placebo, although some secondary measures did.

Neither literature can lend its findings to the other. Data on one peptide say nothing about the other, and findings for a fragment of thymosin beta-4 do not transfer to the full-length protein, or back. Nor do clinical findings describe what a research reagent will do in an assay: material sold for in-vitro work is a laboratory reagent, not a medicine.

Where TB-500 fits

TB-500 is a research-market name, not a scientific one, and it is not used consistently: it is applied both to synthetic full-length thymosin beta-4 and, by some suppliers, to short fragments built around the sequence LKKTETQ, residues 17–23 of the mature chain. A 2012 study in Drug Testing and Analysis characterized the N-terminally acetylated 17–23 fragment identified in a product sold as TB-500. The two candidates are different molecules — about 4,963 g/mol for full-length thymosin beta-4 against about 889 g/mol for Ac-LKKTETQ, by our calculation — and findings for one do not carry over to the other. Neither has anything to do with thymosin alpha-1. Our guide to what the name TB-500 refers to covers the naming question in detail.

What’s established and what isn’t

Telling them apart when sourcing in Canada

With names this close, mix-ups are easy. When the question is thymosin alpha-1 vs thymosin beta-4 on a product page, a short checklist covers most of it:

• Read the full name and sequence, not the abbreviation. TA1 and TB4, or Tα1 and Tβ4, differ by one character; a listing should give the sequence and show the N-terminal acetyl group.
• Check the mass against the right value. Calculated average masses are 3,108.3 g/mol for N-acetylated thymosin alpha-1 and 4,963.5 g/mol for N-acetylated thymosin beta-4; without its acetyl group, either would be about 42 lighter. Our guide to reading a peptide mass spectrum explains charge states and adducts.
• Know the likely variants. Thymosin beta-4 contains one methionine, a residue Nugrahadi and colleagues list as particularly susceptible to oxidation, so a form about 16 mass units heavier is a plausible degradation product. Thymosin alpha-1 has no methionine; its C-terminal residue is asparagine, a residue type that can deamidate, which would add about 1.
• Do not confuse precursor and peptide. Prothymosin alpha (111 residues as encoded) is not thymosin alpha-1 (28).
• Keep identity and suitability apart. A matching mass is evidence of which molecule is in the vial; it says nothing about suitability for any use outside the laboratory.
• Ask when a listing is unclear. Our Contact page handles sequence and documentation questions. We are a supplier too, so apply these checks to our listings as you would to anyone else’s.

Pure Peptides Canada is a Canadian-owned supplier based in Toronto; prices are in Canadian dollars, and orders ship tracked from inside Canada to every province and territory.

Frequently asked questions